Securian Asset Management Inc. Decreases Stake in DaVita Inc. $DVA

Securian Asset Management Inc. reduced its holdings in DaVita Inc. (NYSE:DVA) by 8.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 2,052 shares of the company’s stock after selling 200 shares during the period. Securian Asset Management Inc.’s holdings in DaVita were worth $292,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Invesco Ltd. lifted its stake in shares of DaVita by 3.4% in the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock worth $251,322,000 after buying an additional 53,402 shares in the last quarter. Northern Trust Corp lifted its stake in shares of DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after buying an additional 149,858 shares in the last quarter. Gates Capital Management Inc. lifted its stake in shares of DaVita by 0.7% in the first quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock worth $110,476,000 after buying an additional 4,698 shares in the last quarter. Amundi lifted its stake in shares of DaVita by 16.0% in the first quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after buying an additional 71,304 shares in the last quarter. Finally, Epoch Investment Partners Inc. lifted its stake in shares of DaVita by 10.7% in the first quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after buying an additional 39,485 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DVA. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Friday. Bank of America cut their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Barclays cut their price objective on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a research report on Thursday, October 9th. Truist Financial set a $140.00 price objective on shares of DaVita in a research report on Tuesday, October 14th. Finally, Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $153.25.

DaVita Price Performance

Shares of DVA opened at $129.27 on Friday. DaVita Inc. has a 1-year low of $122.93 and a 1-year high of $179.60. The stock has a market cap of $9.24 billion, a PE ratio of 12.71, a P/E/G ratio of 0.93 and a beta of 1.13. The firm has a 50-day simple moving average of $132.02 and a two-hundred day simple moving average of $137.65.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same period last year, the business earned $2.00 earnings per share. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.